Eculizumab cessation in atypical hemolytic uremic syndrome

Samuel A. Merrill; Zachary D. Brittingham; Xuan Yuan; Alison R. Moliterno; C. John Sperati; Robert A. Brodsky

doi:10.1182/blood-2017-02-770214

Eculizumab cessation in atypical hemolytic uremic syndrome

Samuel A. Merrill, Zachary D. Brittingham, Xuan Yuan, Alison R. Moliterno, C. John Sperati, Robert A. Brodsky

School of Medicine

Research output: Contribution to journal › Letter › peer-review

41 Scopus citations

Original language	English (US)
Pages (from-to)	368-372
Number of pages	5
Journal	Blood
Volume	130
Issue number	3
DOIs	https://doi.org/10.1182/blood-2017-02-770214
State	Published - Jul 20 2017

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2017-02-770214

Cite this

@article{9387e2ac3bc240dca6aeec1ef7970c2b,

title = "Eculizumab cessation in atypical hemolytic uremic syndrome",

author = "Merrill, {Samuel A.} and Brittingham, {Zachary D.} and Xuan Yuan and Moliterno, {Alison R.} and Sperati, {C. John} and Brodsky, {Robert A.}",

note = "Funding Information: S.A.M. is supported by National Institutes of Health, National Heart, Lung, and Blood Institute hematology fellowship training grant T32 HL007525. This study was supported by National Institutes of Health, National Heart, Lung, and Blood Institute RO1 90069145. S.A.M. participates on the True North Therapeutics advisory board. C.J.S. receives research funding from Alexion Pharmaceuticals as site principal investigator for the International aHUS registry and is the Chair of the Data Monitoring Committee for the ALXN1210-aHUS-311/ 312 clinical trial. R.A.B. receives research support from Alexion Pharmaceuticals and Apellis Pharmaceuticals and serves on the advisory boards for Alexion Pharmaceuticals, Achillion Pharmaceuticals, and Apellis Pharmaceuticals. The remaining authors declare no competing financial interests.",

year = "2017",

month = jul,

day = "20",

doi = "10.1182/blood-2017-02-770214",

language = "English (US)",

volume = "130",

pages = "368--372",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "3",

}

TY - JOUR

T1 - Eculizumab cessation in atypical hemolytic uremic syndrome

AU - Merrill, Samuel A.

AU - Brittingham, Zachary D.

AU - Yuan, Xuan

AU - Moliterno, Alison R.

AU - Sperati, C. John

AU - Brodsky, Robert A.

N1 - Funding Information: S.A.M. is supported by National Institutes of Health, National Heart, Lung, and Blood Institute hematology fellowship training grant T32 HL007525. This study was supported by National Institutes of Health, National Heart, Lung, and Blood Institute RO1 90069145. S.A.M. participates on the True North Therapeutics advisory board. C.J.S. receives research funding from Alexion Pharmaceuticals as site principal investigator for the International aHUS registry and is the Chair of the Data Monitoring Committee for the ALXN1210-aHUS-311/ 312 clinical trial. R.A.B. receives research support from Alexion Pharmaceuticals and Apellis Pharmaceuticals and serves on the advisory boards for Alexion Pharmaceuticals, Achillion Pharmaceuticals, and Apellis Pharmaceuticals. The remaining authors declare no competing financial interests.

PY - 2017/7/20

Y1 - 2017/7/20

UR - http://www.scopus.com/inward/record.url?scp=85026289291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026289291&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-02-770214

DO - 10.1182/blood-2017-02-770214

M3 - Letter

C2 - 28461395

AN - SCOPUS:85026289291

SN - 0006-4971

VL - 130

SP - 368

EP - 372

JO - Blood

JF - Blood

IS - 3

ER -

Eculizumab cessation in atypical hemolytic uremic syndrome

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this